Open-Label Long-Term Safety Study of AXS-07 for the Acute Treatment of Migraine

• Status: Completed
• Trial end date: 2020-09-22
• Target enrollment: 0
• Participant gender: All

Summary

Study to evaluate the long-term safety of chronic intermittent use of AXS-07 and to assess the effect of AXS-07 on migraine symptoms following repeated treatment of migraine attacks.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Axsome Therapeutics, Inc.
• Treatments: Meloxicam; Rizatriptan

Criteria

Inclusion Criteria:

• Has participated in a prior study with AXS-07 for the treatment of migraine

Exclusion Criteria:

• Has previously received any investigational drug or device or investigational therapy within 30 days before Screening, other than AXS-07

• Pregnant, breastfeeding, or planning to become pregnant or breastfeed during the study